In Depth 11 Jan 2023 Drug repurposing emerges as viable option for rare disease treatment With few options available for the treatment of rare diseases, the practice of drug repurposing has gained traction as an effective strategy. With genome sequencing revealing new rare diseases, it is now known that at least 5% of the world population lives with a rare disease. Drug development must pick up the pace to keep […] January 11, 2023 - 7 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 2023 life sciences industry trends: adopting a digital-first mindset By Pat Jenakanandhini, chief product officer, ArisGlobal With the new year here, life science organizations have reached technology crossroads in choosing whether to embrace a digital-first mindset and adopt innovative digital technologies or hold fast to legacy processes. Digital transformation has driven newer technologies designed to improve efficiency, patient care and workflows. Those who choose […] January 11, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What the new year holds for clinical research Catherine Gregor is the chief clinical trial officer at Florence Healthcare. The company’s clinical trial software is used in more than 12,000 research sites in 45 countries for management of documents, data, and workflows. We asked Gregor about the clinical trial technology landscape in 2023. Why is remote clinical research connectivity so important? Remote connectivity […] January 11, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Silo Pharma looks into the 2023 psychedelics crystal ball Labiotech had the opportunity to ask James Kuo, vice president of R&D at Silo Pharma Inc., about his predictions for the field of psychedelic research in 2023. Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare […] January 11, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Clinical trends for 2023 By Richard Staines, account director, Optimum Strategic Communications Few would deny that the decade has had a turbulent start, but after the tragedies of the COVID-19 pandemic and the Ukraine war, there’s hope that 2023 will see a new wave of clinical research. Exciting new technologies such as gene editing, gene therapy and a next […] January 11, 2023 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What’s in store for biotech in 2023? Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […] January 11, 2023 - 14 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 2023: A pivotal time for medicine as it enters a new ‘personalized’ era By Hakim Yadi, co-founder and CEO of Closed Loop Medicine The traditional healthcare delivery model is designed to cater to the masses, rather than the individual. Administering treatments based on the overall safety and efficacy demonstrated in large-scale clinical trials, and not taking into consideration individual responses to such treatments, is resulting in poorer outcomes […] January 11, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 We DUB this target ‘druggable’ By Sheelagh Frame, CSO at Ubiquigent Modulation of the ubiquitin-proteasome system (UPS) presents a rich source for drug discovery. Recent years have seen the clinical validation of proteolysis-targeting chimeras (PROTACs) unlock the ability to drug the undruggable, by exploiting E3 ligases to mediate targeted protein degradation (TPD), paving the way to tackle exciting new drug […] January 11, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Biotech in Asia: looking forward to 2023 Masahiko Hayakawa, head of targeted protein degradation at Astellas Pharma Inc., gives us some insights into the state of the biopharma industry in 2023. Astellas is a Japanese headquartered pharmaceutical company active in more than 70 countries around the world. It promotes a ‘focus area approach’ designed to identify opportunities for the continuous creation of […] January 11, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Lifesciences and biotech in 2023 A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […] January 11, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 10 Jan 2023 Innovative biomaterials are revolutionizing tissue regeneration Scientists are increasingly realizing the potential of biomaterials to help with many tasks. A key area biomaterials are being used in is tissue engineering and regeneration, something several biotechs and academic labs are currently exploring. Biomaterials are materials or substances designed to function in a biological environment, which may or may not be made of […] January 10, 2023 - 14 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 9 Jan 2023 The biggest private biotech investments in December 2022 The companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology and manufacturing players attracted the biggest funding rounds. We’ve hit 2023 and a lot of biotech fundraising took place in the final month of 2022. We’ve gathered the biggest biotech investments that went to private […] January 9, 2023 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email